アブストラクト
| Title | ビタミンD製剤 |
|---|---|
| Subtitle | 特集 CKD-MBD up to date 【治療薬の進歩】 |
| Authors | 稲熊大城** |
| Authors (kana) | |
| Organization | **藤田医科大学医学部 腎臓内科学 |
| Journal | 腎と透析 |
| Volume | 88 |
| Number | 1 |
| Page | 57-61 |
| Year/Month | 2020 / 1 |
| Article | 報告 |
| Publisher | 東京医学社 |
| Abstract | 「はじめに」 活性型ビタミンDは, 主として腎臓で産生されるため, 慢性腎臓病(CKD)患者においては腎機能の低下とともに, 早期より血清濃度の低下がみられる. 特に, 透析患者は高度のビタミンD欠乏状態であり, ビタミンD製剤を補充することは理に叶っている. しかしながら, これまでの歴史の中で, 透析を含むCKD患者に対して, ビタミンD補充あるいは活性型ビタミンD製剤投与の可否については揺れ動いてきており, 現在でもエビデンスは十分とはいえない. 「I ビタミンD代謝」 天然型ビタミンDは, 食物中に含まれているもの以外としては, 皮膚に紫外線が作用することで7, 8デヒドロコレステロールから産生される. 天然型ビタミンDは肝において, 25水酸化酵素によって, 25ヒドロキシビタミンD(25D)となる. 25Dは, 血中ではビタミンD結合蛋白と結合し, 糸球体で濾過された後, 近位尿細管細胞で再吸収される. |
| Practice | 臨床医学：内科系 |
| Keywords | ビタミンD, VDRA |
- 全文ダウンロード： 従量制、基本料金制の方共に1,023円(税込) です。
参考文献
- 1) Dusso AS : Kidney disease and vitamin D levels : 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation. Kidney Int Suppl 1 : 136-141, 2011
- 2) Melamed ML, Chonchol M, Gutierrez OM, et al : The role of vitamin D in CKD stages 3 to 4 : report of a Scientific Workshop Sponsored by the National Kid-ney Foundation. Am J Kidney Dis 72 : 834-845, 2018
- 3) Fukagawa M, Yokoyama K, Koiwa F, et al : Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 17 : 247-288, 2013
- 4) Ketteler M, Block GA, Evenepoel P, et al : Executive summary of the 2017 KDIGO Chronic Kidney Dis-ease-Mineral and Bone Disorder(CKD-MBD)Guide-line Update : what's changed and why it matters. Kidney Int 92 : 26-36, 2017
- 5) Umar M, Sastry KS, Chouchane AI : Role of vitamin D beyond the skeletal function : a review of the molecular and clinical studies. Int J Mol Sci 19 : E1618, 2018
残りの15件を表示する
- 6) Teng M, Wolf M, Lowrie E, et al : Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349 : 446-456, 2003
- 7) Shoji T, Shinohara K, Kimoto E, et al : Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vita-min D3 users in a haemodialysis population. Nephrol Dial Transplant 19 : 179-184, 2004
- 8) Sugiura S, Inaguma D, Kitagawa A, et al : Adminis-tration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events. Clin Exp Nephrol 14 : 43-50, 2010
- 9) Inaguma D, Ito E, Koide S, et al : Combination ther-apy with renin-angiotensin system blockers and vitamin D receptor activators for predialysis patients is associated with the incidence of cardiovascular events after dialysis initiation : a multicenter nonran-domized prospective cohort study. Cardiorenal Med 8 : 71-81, 2017
- 10) Wang AY, Fang F, Chan J, et al : Effect of paricalcitol on left ventricular mass and function in CKD-the OPERA trial. J Am Soc Nephrol 25 : 175-186, 2014
- 11) Thadhani R, Appelbaum E, Pritchett Y, et al : Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease : the PRIMO randomized controlled trial. JAMA 307 : 674-684, 2012
- 12) J-DAVID Investigators, Shoji T, Inaba M, et al : Effect of oral alfacalcidol on clinical outcomes in patients without secondary hyperparathyroidism receiving maintenance hemodialysis : The J-DAVID Random-ized Clinical Trial. JAMA 320 : 2325-2334, 2018
- 13) Raggi P, Chertow GM, Torres PU, et al : The ADVANCE study : a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26 : 1327-1339, 2011
- 14) Chertow GM, Block GA, Correa-Rotter R, et al : Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367 : 2482-2494, 2012
- 15) Moe SM, Abdalla S, Chertow GM, et al : Effects of cinacalcet on fracture events in patients receiving hemodialysis : The EVOLVE Trial. J Am Soc Nephrol 26 : 1466-1475, 2015
- 16) Lu CL, Yeih DF, Hou YC, et al : The emerging role of nutritional vitamin D in secondary hyperparathy-roidism in CKD. Nutrients 10 : E1890, 2018
- 17) Ritter C, Miller B, Coyne DW, et al : Paricalcitol and cinacalcet have disparate actions on parathyroid oxy-phil cell content in patients with chronic kidney dis-ease. Kidney Int 92 : 1217-1222, 2017
- 18) Ritter CS, Haughey BH, Miller B, et al : Differential gene expression by oxyphil and chief cells of human parathyroid glands. J Clin Endocrinol Metab 97 : E1499-E1505, 2012
- 19) Kalantar-Zadeh K, Kovesdy CP : Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol 4 : 1529-1539, 2009
- 20) Sprague SM, Silva AL, Al-Saghir F, et al : Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. Am J Nephrol 40 : 535-545, 2014
